PDS Biotechnology Corpora... (PDSB)
| Bid | 1.25 |
| Market Cap | 49.57M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -41.22M |
| EPS (ttm) | -1.17 |
| PE Ratio (ttm) | -1.13 |
| Forward PE | -1.05 |
| Analyst | Buy |
| Ask | 1.33 |
| Volume | 487,522 |
| Avg. Volume (20D) | 495,521 |
| Open | 1.37 |
| Previous Close | 1.36 |
| Day's Range | 1.30 - 1.43 |
| 52-Week Range | 1.20 - 6.68 |
| Beta | 1.88 |
About PDSB
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclini...
Analyst Forecast
According to 3 analyst ratings, the average rating for PDSB stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 956.60% from the latest price.
3 days ago · proactiveinvestors.co.uk
EMV Capital portfolio company PDS Biotechnology raises $11mlnEMV Capital plc (AIM: EMVC) portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB) has raised $11 million, through an equity funding. PDS, which is focussed on immunotherapies, sold around 7.3...